<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cetirizine (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cetirizine (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cetirizine (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="113449" href="/d/html/113449.html" rel="external">see "Cetirizine (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="113447" href="/d/html/113447.html" rel="external">see "Cetirizine (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50183048"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Allergy (Cetirizine) [OTC];</li>
<li>Allergy Relief (Cetirizine) [OTC];</li>
<li>Allergy Relief Cetirizine [OTC];</li>
<li>Allergy Relief Childrens [OTC];</li>
<li>Allergy Relief/Indoor/Outdoor [OTC];</li>
<li>Cetirizine HCl Allergy Child [OTC];</li>
<li>Cetirizine HCl Childrens Alrgy [OTC];</li>
<li>Cetirizine HCl Childrens [OTC] [DSC];</li>
<li>FT All Day Allergy 24 Hour [OTC];</li>
<li>FT All Day Allergy [OTC];</li>
<li>FT Allergy Relief Childrens [OTC];</li>
<li>GoodSense All Day Allergy [OTC];</li>
<li>Quzyttir;</li>
<li>ZyrTEC Allergy Childrens [OTC];</li>
<li>ZyrTEC Allergy [OTC];</li>
<li>ZyrTEC Childrens Allergy [OTC];</li>
<li>ZyrTEC [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53731145"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Cetirizine;</li>
<li>APO-Cetirizine;</li>
<li>BIO-Cetirizine;</li>
<li>JAMP-Cetirizine;</li>
<li>M-Cetirizine;</li>
<li>Mar-Cetirizine;</li>
<li>MINT-Cetirizine;</li>
<li>NRA-Cetirizine;</li>
<li>PMS-Cetirizine;</li>
<li>Priva-Cetirizine [DSC];</li>
<li>Reactine;</li>
<li>TEVA Cetirizine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50183052"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Histamine H<sub>1</sub> Antagonist;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist, Second Generation;</li>
<li>
                        Piperazine Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F50183080"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7304aaf-2fc4-4567-aab9-fef6fca1cc0b">Allergic rhinitis or conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis or conjunctivitis:</b>
<b>Oral:</b> 10 mg once daily; alternatively, may be given as needed 2 to 5 hours before exposure to allergen, although this may be less effective than daily administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-deShazo.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-deShazo.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC labeling (patient-guided therapy for symptoms of hay fever or other upper respiratory allergies):</i> 5 to 10 mg once daily (maximum: 10 mg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a061ea2e-80f2-47e6-8f64-e82220292159">Anaphylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms) (off-label use): Note:</b> Do not use for initial or sole treatment of anaphylaxis because H<sub>1</sub> antihistamines do not relieve upper or lower airway obstruction or shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-17620060','lexi-content-ref-21377030','lexi-content-ref-26525001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-17620060','lexi-content-ref-21377030','lexi-content-ref-26525001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 10 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-Campbell.1','lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-Campbell.1','lexi-content-ref-21377030'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="efde08fa-6871-4b29-baeb-2d79f4a232f3">Angioedema, acute allergic or recurrent idiopathic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema, acute allergic or recurrent idiopathic (off-label use): Note:</b> Not indicated for angioedema with anaphylaxis; use epinephrine if anaphylaxis symptoms are present (ie, risk of airway or cardiovascular compromise is present) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28081650','lexi-content-ref-Zuraw.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28081650','lexi-content-ref-Zuraw.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg once or twice daily; may increase up to 20 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24673465','lexi-content-ref-28081650','lexi-content-ref-Zuraw.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24673465','lexi-content-ref-28081650','lexi-content-ref-Zuraw.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0617bcf-4c72-4048-820f-7cedee1ad687">Infusion reaction, premedication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion reaction, premedication (adjunct) (alternative agent) (off-label use): Note:</b> Used in some protocols as an alternative to a sedating antihistamine (eg, diphenhydramine). An optimal premedication regimen has not been identified; refer to institutional protocols as variations exist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Castells.2019','lexi-content-ref-30419768','lexi-content-ref-Kirkham.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Castells.2019','lexi-content-ref-30419768','lexi-content-ref-Kirkham.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg typically administered 30 to 60 minutes prior to infusion of certain chemotherapy agents or biologics; may be given with an H<sub>2</sub> antihistamine (eg, ranitidine) and/or a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Castells.2019','lexi-content-ref-30419768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Castells.2019','lexi-content-ref-30419768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f65880a4-134b-4d60-99af-28a6f3dd6eaa">Urticaria, new onset and chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset and chronic spontaneous: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>New onset:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (off-label use):</b> Initial: 10 mg once daily. If symptom control is inadequate, may immediately increase to 10 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Asero.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Asero.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 10 mg once daily as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic spontaneous:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 10 mg once daily. If symptom control is inadequate, may increase in increments of 10 mg/day every 1 to 4 weeks up to 20 mg twice daily. Periodically reevaluate necessity for continued treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khan.2019','lexi-content-ref-29336054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khan.2019','lexi-content-ref-29336054'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990319"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> No dosage adjustment necessary (formulation only intended for short-term use).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: Note:</b> Renally adjusted dose recommendations are based on usual doses of 5 to 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;31 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 11 to ≤31 mL/minute: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≤10 mL/minute: 5 mg once every 48 hours; may increase to 5 mg once daily based on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> &lt;10% dialyzable; 5 mg 3 times per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11528239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11528239'])">Ref</a></span>); may increase to 5 mg once daily based on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1970299','lexi-content-ref-11528239','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1970299','lexi-content-ref-11528239','lexi-content-ref-Expert.DOR'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: </b>Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): 5 mg once every 48 hours; may increase to 5 mg once daily based on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987650"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Mild to severe impairment: 5 mg once daily.</p></div>
<div class="block doe drugH1Div" id="F50183082"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Upper respiratory allergies, urticaria:</b> Oral: 5 mg once daily (maximum dose: 5 mg daily). The previously available prescription product recommended a maximum dose of 10 mg once daily in patients &lt;77 years of age or 5 mg once daily in patients ≥77 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pfizer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pfizer.1'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F50183081"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="113447" href="/d/html/113447.html" rel="external">see "Cetirizine (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c8123d5-63e1-4fd0-b4d4-fd52eac80de3">Allergic rhinitis, perennial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic r</b>
<b>hinitis, perennial: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants 6 to &lt;12 months: Oral: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 12 to 23 months: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d0055c1-25bc-4dfa-b958-a9da36b3e3ad">Allergic symptoms, hay fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic symptoms, hay fever: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily; maximum daily dose: 5 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: 5 to 10 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5372b8ee-a43e-41d5-8637-e18e48ce3f75">Anaphylaxis; adjunctive for cutaneous symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis; adjunctive for cutaneous symptoms:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22211074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22211074'])">Ref</a></span>): <b>Note:</b> Do not use for initial or sole treatment of anaphylaxis; H<sub>1</sub> antihistamines are not effective for upper or lower airway obstruction or shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-21377030','lexi-content-ref-26525001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-21377030','lexi-content-ref-26525001'])">Ref</a></span>). If cutaneous symptoms persist, dose may be repeated in 24 hours (see <b>Urticaria, acute</b> dosing).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;2 years: Oral: 2.5 mg once.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: Oral 2.5 to 5 mg once.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;5 years and Adolescents: Oral: 5 to 10 mg once.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d9d94d9-ca6f-40af-aa3f-2ce90b91c7c5">Urticaria, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, acute: </b></p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months to Children ≤5 years: 2.5 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 11 years: 5 mg or 10 mg every 24 hours; reserve higher dose for more severe symptoms.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: 10 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22211074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22211074'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months and Children &lt;2 years: Oral: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 5 years: Oral: 2.5 to 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;5 years and Adolescents: Oral: 5 to 10 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e59a61ec-4a7a-40f9-83a5-0a8d439e15d5">Urticaria, chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic spontaneous:</b> Limited data available in Children &gt;5 years and Adolescents. <b>Note:</b> Considered first-line therapy for management of chronic urticaria; if response inadequate after 2 to 4 weeks of therapy or symptoms intolerable, consider increasing the dose of cetirizine (as age and weight permits) as second-line treatment rather than changing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29336054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29336054'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 6 to &lt;12 months: Oral: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥12 months and Children &lt;2 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily; maximum daily dose: 5 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: Oral: 5 mg once daily or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31416456','lexi-content-ref-DelPozzo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31416456','lexi-content-ref-DelPozzo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31416456','lexi-content-ref-DelPozzo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31416456','lexi-content-ref-DelPozzo.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084406"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>Note:</b> Has only been evaluated for acute indications (short-term therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;6 years: Avoid use in patients with any degree of renal impairment; has not been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Moderate to severe impairment; end-stage renal disease on dialysis: No adjustment necessary; monitor for antihistamine side effects and adjust therapy if needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Decrease dose by 50%.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis or peritoneal dialysis: Decrease dose by 50%.</p></div>
<div class="block dohp drugH1Div" id="F51084407"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>Note:</b> Has only been evaluated for acute indications (short-term therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months to Children &lt;6 years: Avoid use with hepatic impairment; has not been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: No dosage adjustment required; monitor for antihistamine side effects and adjust therapy if needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Infants ≥6 months, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55850056"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cetirizine may cause CNS depression, including <b>sedated state</b>, <b>drowsiness</b>, and <b>fatigue</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9066452','lexi-content-ref-31827796','lexi-content-ref-10784544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9066452','lexi-content-ref-31827796','lexi-content-ref-10784544'])">Ref</a></span>). There are rare reports of <b>psychosis</b> and <b>delusion</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33547112','lexi-content-ref-23673913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33547112','lexi-content-ref-23673913'])">Ref</a></span>). In overdose in children, sedation is more likely to occur than with other second-generation antihistamines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14754980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14754980'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; low brain uptake, binding to ~30% of H1 cerebral receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9066452','lexi-content-ref-31827796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9066452','lexi-content-ref-31827796'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: May occur after 1 or 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10582735','lexi-content-ref-8621847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10582735','lexi-content-ref-8621847'])">Ref</a></span>). Onset of psychosis has occurred 2 to 7 days after initiation of cetirizine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33547112','lexi-content-ref-23673913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33547112','lexi-content-ref-23673913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10348091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10348091'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10582735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10582735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• More sedating than other second-generation antihistamines, including loratadine and fexofenadine, but less sedating than first-generation antihistamines such as diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10582735','lexi-content-ref-10348091','lexi-content-ref-10784544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10582735','lexi-content-ref-10348091','lexi-content-ref-10784544'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F50183065"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Drowsiness (adolescents and adults: 11% to 14%; children: 2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 1</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, headache (children: 14%; adults: &lt;1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Cetirizine (Systemic): Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Cetirizine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Cetirizine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">215</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">309</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">161</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">309</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg or 10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,034</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,612</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure (&lt;2%), chest pain (&lt;2%), edema (&lt;2%), facial edema (&lt;2%), flushing (&lt;2%), hypertension (&lt;2%), lower extremity edema (&lt;2%), palpitations (&lt;2%), peripheral edema (&lt;2%), syncope (&lt;2%), tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (&lt;2%), alopecia (&lt;2%), bullous rash (&lt;2%), cutaneous nodule (&lt;2%), dermatitis (&lt;2%), diaphoresis (&lt;2%), eczema (&lt;2%), erythematous rash (&lt;2%), furunculosis (&lt;2%), hyperkeratosis (&lt;2%), hypertrichosis (&lt;2%), maculopapular rash (&lt;2%), pallor (&lt;2%), pruritus (&lt;2%), seborrhea (&lt;2%), skin photosensitivity (&lt;2%), skin rash (&lt;2%), urticaria (&lt;2%), xeroderma (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (&lt;2%), dehydration (&lt;2%), diabetes mellitus (&lt;2%), heavy menstrual bleeding (&lt;2%), hot flash (&lt;2%), increased thirst (&lt;2%), intermenstrual bleeding (&lt;2%), weight gain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children: 4% to 6%), ageusia (&lt;2%), anorexia (&lt;2%), aphthous stomatitis (&lt;2%), constipation (&lt;2%), dental caries (&lt;2%), diarrhea (children: 2% to 3%), dysgeusia (&lt;2%), dyspepsia (&lt;2%), enlargement of abdomen (&lt;2%), eructation (&lt;2%), flatulence (&lt;2%), gastritis (&lt;2%), hemorrhoids (&lt;2%), increased appetite (&lt;2%), melena (&lt;2%), nausea (children: 3%), sialorrhea (&lt;2%), stomatitis (&lt;2%), tongue discoloration (&lt;2%), vomiting (children: 2% to 3%), xerostomia (adolescents and adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (&lt;2%), dysmenorrhea (&lt;2%), dysuria (&lt;2%), hematuria (&lt;2%), leukorrhea (&lt;2%), mastalgia (&lt;2%), urinary frequency (&lt;2%), urinary incontinence (&lt;2%), urinary retention (&lt;2%), urinary tract infection (&lt;2%), vaginitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemophthalmos (&lt;2%), lymphadenopathy (&lt;2%), purpuric disease (&lt;2%), rectal hemorrhage (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (&lt;2%), tongue edema (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (&lt;2%), agitation (&lt;2%), altered sense of smell (&lt;2%), amnesia (&lt;2%), anxiety (&lt;2%), ataxia (&lt;2%), confusion (&lt;2%), depersonalization (&lt;2%), depression (&lt;2%), dizziness (adolescents and adults: 2%), emotional lability (&lt;2%), euphoria (&lt;2%), fatigue (4% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 2</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, hyperesthesia (&lt;2%), hypertonia (&lt;2%), hypoesthesia (&lt;2%), impaired concentration (&lt;2%), insomnia (≤9%), malaise (≤4%), migraine (&lt;2%), myasthenia (&lt;2%), nervousness (&lt;2%), nightmares (&lt;2%), pain (&lt;2%), paralysis (&lt;2%), paresthesia (&lt;2%), rigors (&lt;2%), sleep disorder (&lt;2%), twitching (&lt;2%), vertigo (&lt;2%), voice disorder (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Cetirizine (Systemic): Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Cetirizine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Cetirizine [Systemic])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg or 10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents &amp; adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg or 10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,034</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,612</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), arthritis (&lt;2%), asthenia (&lt;2%), back pain (&lt;2%), hyperkinetic muscle activity (&lt;2%), lower limb cramp (&lt;2%), myalgia (&lt;2%), myelitis (&lt;2%), osteoarthrosis (&lt;2%), tremor (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance (&lt;2%), blepharoptosis (&lt;2%), blindness (&lt;2%), conjunctivitis (&lt;2%), eye pain (&lt;2%), glaucoma (&lt;2%), periorbital edema (&lt;2%), visual field defect (&lt;2%), xerophthalmia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (&lt;2%), otalgia (&lt;2%), ototoxicity (&lt;2%), tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (&lt;2%), bronchospasm (children: 3%), dyspnea (&lt;2%), epistaxis (children: 4%), hyperventilation (&lt;2%), increased bronchial secretions (&lt;2%), nasal polyposis (&lt;2%), pharyngitis (2% to 6%), pneumonia (&lt;2%), respiratory system disorder (&lt;2%), rhinitis (&lt;2%), sinusitis (&lt;2%), upper respiratory tract infection (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Presyncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Feeling hot</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (transient, reversible)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Irritability</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fussiness in an infant or toddler</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Severe hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Fong 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Pompili 2004), increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Afonso 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, delusion (Garden 2013), hallucination, psychosis (Croitoru 2021), sedated state (Corsico 2019), seizure, suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Orofacial dyskinesia (Romo 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis</p></div>
<div class="block coi drugH1Div" id="F50183062"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cetirizine, hydroxyzine, levocetirizine, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to piperazine derivatives; severe renal impairment (CrCl &lt;10 mL/minute).</p></div>
<div class="block war drugH1Div" id="F50183063"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pruritus: Rebound pruritus has been reported within several days after stopping cetirizine, usually after long-term (eg, months to years) use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution; consider dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution; consider dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; may be more sensitive to adverse effects.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878818"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F50183096"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief (Cetirizine): 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Allergy: 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Quzyttir: 10 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief Childrens: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL) [alcohol free, dye free, gluten free, sugar free; contains methylparaben, propylene glycol, propylparaben; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL [DSC]) [alcohol free, sugar free; contains methylparaben, propylene glycol, propylparaben; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetirizine HCl Allergy Child: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (120 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (118 mL) [dye free; contains methylparaben, propylene glycol, propylparaben; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief Childrens: 5 mg/5 mL (120 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense All Day Allergy: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense All Day Allergy: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate, sorbitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Childrens Allergy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Childrens Allergy: 5 mg/5 mL (30 mL, 118 mL, 236 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (120 mL, 473 mL, 480 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy (Cetirizine): 10 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief (Cetirizine): 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief Cetirizine: 5 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief Cetirizine: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief Cetirizine: 10 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief/Indoor/Outdoor: 10 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT All Day Allergy: 10 mg [gluten free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT All Day Allergy 24 Hour: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense All Day Allergy: 10 mg [gluten free; contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Allergy: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Childrens Allergy: 2.5 mg [dye free; contains corn starch; grape flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetirizine HCl Childrens: 5 mg [DSC], 10 mg [DSC] [contains aspartame, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC: 10 mg [dye free; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Childrens Allergy: 10 mg [dye free; contains corn starch; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Allergy: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Allergy Childrens: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZyrTEC Allergy Childrens: 10 mg [citrus flavor]</p></div>
<div class="block geq drugH1Div" id="F50183051"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F50183098"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (ZyrTEC Allergy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Cetirizine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.47 - $5.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.47 - $5.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (ZyrTEC Childrens Allergy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (ZyrTEC Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Quzyttir Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $372.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (ZyrTEC Childrens Allergy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (ZyrTEC Allergy Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cetirizine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.49 - $2.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.05 - $2.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (ZyrTEC Allergy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53731146"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Reactine: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg</p></div>
<div class="block adm drugH1Div" id="F50183087"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Chewable tablet: Chew tablet before swallowing; may be taken with or without water.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Injection: For IV use only; do not administer IM or SUBQ; administer as an IV push over 1 to 2 minutes.</p></div>
<div class="block admp drugH1Div" id="F52614660"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:4em;">Chewable tablet: Chew tablet before swallowing; may be taken with or without water.</p>
<p style="text-indent:-2em;margin-left:4em;">Dissolving tablet: Allow tablet to melt in mouth; may be taken with or without water.</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid: Administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Administer IV undiluted over 1 to 2 minutes; do not administer IM or SubQ.</p></div>
<div class="block use drugH1Div" id="F50183056"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Allergic rhinitis:</b> Relief of symptoms associated with allergic rhinitis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Urticaria, chronic spontaneous:</b> Treatment of uncomplicated skin manifestations of chronic spontaneous urticaria.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Urticaria, new onset:</b> Treatment of new-onset (acute) urticaria.</p></div>
<div class="block off-label drugH1Div" id="F53017319"><span class="drugH1">Use: Off-Label: Adult</span><p>Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms); Angioedema, acute allergic or recurrent idiopathic; Infusion reaction, premedication</p></div>
<div class="block mst drugH1Div" id="F50183043"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cetirizine may be confused with sertraline, stavudine</p>
<p style="text-indent:-2em;margin-left:4em;">Quzyttir may be confused with Qsymia</p>
<p style="text-indent:-2em;margin-left:4em;">ZyrTEC may be confused with Lipitor, Serax, Xanax, Zantac, Zerit, Zocor, ZyPREXA, ZyrTEC-D</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Benadryl international brand name for cetirizine [Great Britain, Philippines], but also the brand name for acrivastine and pseudoephedrine [Great Britain] and several products containing diphenhydramine [US, Canada]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50305416"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F50305413"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin: Cetirizine (Systemic) may enhance the CNS depressant effect of Gabapentin. Cetirizine (Systemic) may decrease the serum concentration of Gabapentin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: May increase the serum concentration of Cetirizine (Systemic). Cetirizine (Systemic) may increase the serum concentration of Pilsicainide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F50183066"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Cetirizine's absorption and maximal concentration are reduced when taken with food. Management: May be taken without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F50183058"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Cetirizine may be used when a second generation antihistamine is needed. The lowest effective dose should be used (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).</p></div>
<div class="block brc drugH1Div" id="F50183061"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Cetirizine is present in breast milk.</p>
<p style="text-indent:0em;margin-top:2em;">Drowsiness and irritability have been reported in breastfed infants exposed to antihistamines (Ito 1993). In general, second generation antihistamines (eg, cetirizine) are less sedating as compared to their first generation counterparts. If a breastfed infant is exposed to a second generation antihistamine via breast milk, they should be monitored for irritability, jitteriness, or drowsiness (Butler 2014).</p>
<p style="text-indent:0em;margin-top:2em;">When treatment with an antihistamine is needed in breastfeeding women for the treatment of rhinitis or urticaria, a second generation antihistamine, such as cetirizine, is preferred. The lowest effective dose should be used (BSACI [Powell 2015]; BSACI [Scadding 2017]; Butler 2014; Zuberbier 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of breastfeeding (Messinis 1985).</p></div>
<div class="block mop drugH1Div" id="F50183089"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Relief of symptoms, sedation, mental alertness, and anticholinergic effects.</p></div>
<div class="block pha drugH1Div" id="F50183069"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract</p></div>
<div class="block phk drugH1Div" id="F50183070"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Suppression of skin wheal and flare: Oral: 20 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Suppression of skin wheal and flare: Oral: ≥24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Children: 0.7 L/kg; Adults: 0.56 L/kg (Simons 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: Mean: 93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Limited hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children: 6.2 hours; Adults: 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 1 hour; IV: 108 seconds.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (70%; 50% as unchanged drug); feces (10%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50222501"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cetgel | Cetmax | Cetralon | Finallerg | Gencet | Glotrizine | Omcet | Zeran | Zetop | Zyrtec</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alernix 24 Pediatrico | Alernix 24 rapida accion | Alidial | Atopix | Cabal | Cetizine | Cetriler | Gripaben Aller | Salvalerg | Stopaler | Zyrtec</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zirtek | Zyrtec</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alzene | Amcal cetirizine | Apo cetirizine | Chemists own childrens c zine | Histaclear | Little allergies | Pharmacy care cetirizine | Pharmacy choice childrens hayfever &amp; allergy relief | Trust cetirizine | Zyrtec</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acetrin | Acitrin | Actizen | Adtrizin | Alarex | Alatin | Alatrol | Allernil | Asitrol | Atrizin | Atrol | Cesil | Cetizin | Cetril | Cetrin | Cezin | Citin | Citrol | Cizin | Ctz | Dyno | Dyzin | Etizin | Histacet | Moset | Noler | Nosemin | Ontin | Orgy | Procet | Rhinil | Riz | Rizin | Sartec | Silatrol | Tiz | Trin | Trizin | Tytrol | Zervin | Zinal | Zyrtec</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cetirizine Bexal | Cetirizine eurogenerics | Cetirizine teva generics belgium | Cetisandoz | Zyrtec</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Alerid | Allertin | Ceticad | Cetix | Curtec | Zyrtec</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Allersan | Cetiristad | Egirizin | Reactin | Talert | Zodac | Zyrtec</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alersin | Aletir | Cetirtec | Cetrizin | Dicloridrato de cetirizina | Reactine | Zetalerg | Zetir | Zyrtec</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cerzin | Cerzin mepha | Cetallerg | Cetallerg sandoz | Cetirizin mepha | Cetirizin Streuli | Cetirizine helvepharm | Zyrtec</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Airlix | Alerid | Allercet | Ceticad | Cezin | Curtec | Genset | Rinacet | Roncet | Zetry mepha | Zyncet | Zyrtec</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alertop | Cetialer | Findaler | Histalen | Histax | Nonaler | Remitex | Rigotax | Sanaler | Zyrtec</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An di xi si | Ao bo da | Bei fen | Bi te li | Cetirizine | Cetirizine dihydrochloride | Cetrizet | Di di | Jie jie | Lu cheng | Sheng min qing | Shi di | Shuang te | Wei Di Min | Xi ke wei | Xi Li | Xi ning | Xi te rui | Xian li te | Xiu si | Xue ding | Yi meng | Yi Wei Tuo | Ying xin mei shu | Zinit | Zyrtec</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acidrine | Alercet | Alerfrin | Alergex | Alerviden | Allerzitina | Allerzitina kids | Birtex | Bonarazina | Ceriz t | Cetirax | Cetirizina | Cetirizina diclorhidrato | Cetirizina Ecar | Cetirizina MK | Cetirizina WINTHROP | Cetirrinol | Cetiswiss | Cetrine | Expotizina | Histarizina | Mega we care zirin | Nivox | Nolegar | Optiser | Rincetir | Xetrix | Zeridal | Zeridil | Zyrfar | Zyrtec</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alerid | Letizen | Zodac | Zyrtec</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cetirizin | Cetirizin 1a pharma | Cetirizin al | Cetirizin aristo | Cetirizin beta | Cetirizin hexal | Cetirizin Ratiopharm | Cetirizin sandoz | Cetirizin stada | Cetirizin zum einnehmen | Docmorris Cetirizin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Benaday</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Abravia | Alercet | Alerfrin | Alernadina | Alerplus | Alerviden | Amazina | Berak | Cetir | Cetirax | Cetirina | Cetirizina | Cetirizina Inmenol | Cetirizina lam | Cetirizina mamey | Cetirizina MK | Cetirizina sued | Cetizin | Cliartek | Histal | Interant | Kalven | Luterizina | N Cistil | Sinalerg | Talerdin | Tirizin | Zetri | Zinaltec | Zynavic gv | Zyrtec</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alercet | Alerpasol | Alerplax | Amazina | Antialer | Cetirizina | Cetirizina la sante | Cetrine | Ciritex | Cotalil | Flufin allergy | Histax | Respixion | Rhinodina | Rigotax | Talerdin | Tolmex | Zyrtec</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aceterin | Aceterin express | Cetrix | Letizen | Reactin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alerid | Badotirizin | Cetirizine | Cetrak | Cetrichew | Cetritin | Epirizine | Histazine | Histazine 1 | Lergfree | Tomazine | Zyrtec</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alerlisin | Cetirizina cipla | Cetirizina Ranbaxy | Cetirizina Sandoz | Garpon | Ratioalerg | Reactine | Virlix | Zyrtec</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Arcet | Cetirizine dihydrochloride | Finallerg | Zyncet</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cetirizin Ratiopharm | Cetirizin sandoz | Heinix | Senirex | Zyrtec</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alairgix | ALAIRGIX ALLERGIE | Cetirizine Biogaran | Cetirizine EG | Virlix | Zyrtec</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Allergy &amp; Hayfever Relief | AllerTek | Benadryl allergy | Benadryl for Children Allergy Solution | Benadryl one a day relief | Cetirizine | Cetirizine Kent | Cetirizine sandoz | Galpharm hayfever | Hayfever &amp; allergy relief | Hayfever and Allergy Relief | Hayfever relief | LloydsPharmacy antihistamine hayfever relief | Numark Allergy Relief for Children | Piriteze | Piriteze allergy | T&amp;r hay fever | Wockhardt Allergy and Hayfever Relief | Ziralton | Zirtek</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alenstran | Dermizin | Zepholin | Zirtek</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Adezio | Alesof | Allutec | Altirin | Apo cetirizine | Avotec | Cerotec | Cetec | Cetia | Cetihis | Cetirin | Cetirizin | Cetirizine | Cetirizine dihydrochloride | Cetisin | Cetzie | Citriza | Cytec | Jmp cetirizine | Laricetin | Letizen | Mantab | Pharmaniaga cetirizine | Rizine | Simtec | Sunizine | Terizine | Tirizine | Uni-Certec | Vick Zyrt | Vidatec | Zetizine | Zicet | Zymed | Zyrtec</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cetrin Akut | Cetrizin hexal | Parlazin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alerzin | Betarhin | Capritazin | Cerini | Cetaler | Cetinal | Cetirgi | Cetirizine | Cetirizine dihydrochloride | Cetirizine HCL | Cetryn | Cetymin | Falergi | Histrine | Hufarizine | Incidal-od | Intrizin | Lerzin | Nichorizin | Omezyrteks | Ozen | Rinocet | Risina | Ritez | Rozine | Rydian | Ryvel | Ryzen | Simzen | Tiriz | Trisela | Yarizine | Zenriz | Zentris</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Anti hist allergy | Cetrine allergy | Histek | Tiritek allergy | Zirtek | Zynor</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Allergy Care | Histazine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acet | Agicet | Airtis | Alce | Alcet | Alday | Alego | Alerbloc | Alerid | Alertac | Allercet | Allerzine | Allicet | Alocet | Alzine | Ancet | Anzin | Atozine | Atzine | Aurocitin | Batriz | Bealert | Bio act | C zen | Cerizine | Cerzin | Cet | Cetag | Cetariv | Cetcip | Ceten | Ceterezol | Cetfast | Cetgel | Ceti | Ceticad | Cetiminic | Cetin | Cetinam | Cetipen | Cetiriz | Cetirizine | Cetirizine di-hcl | Cetiz | Cetoz | Cetral | Cetramac | Cetrezol | Cetri | Cetride | Cetrifil | Cetrimark | Cetrimol | Cetrina md | Cetrinat | Cetrine | Cetritab | Cetritop | Cetriwin | Cetrizet | Cetrizine | Cetzine | Cez | Cezin | Cistin | Citimed | Citirizine | Citla | Citol | Citrazan | Citri a | Cope | Coszin | Ctz | Ctzine | Cypzine | Cz-3 | Dio-1 | Ekon | Epocrin | Floramin | Fomicet | Hicet | Hisnofil | Histacet | Histazin | Holday | Inalam | Incid-l | Intazin | Lgnil | Locet | Lodizin | Lupicet | Lycet | M-cet | M-triz | Mast 1 | Mdzime | Morazin | Neusonil | Odacet | Okacet | Oncet | One a day | Opticet | Ozocin | Percet | Rhinocet | Rhizin | Rincet | Satrin | Setimed | Setride | Sizon | Stanhist | Supres | Suzicet | Tancet | Triz | Trizin | Tzine | Unicet | Zene | Zimat | Zine | Zircet | Zirtin | Zolase | Zolong | Zyncet | Zyrtec</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Axeramis | Ceteris | Cetirizina actavis | Cetirizina aurobindo | Cetirizina Doc | Cetirizina eg | Cetirizina Fg | Cetirizina Myl | Cetirizina pensa | Cetirizina Ranbaxy | Cetirizina teva | Formistin | Kruzin | Leviorinil | Prizitec | Raingen | Rinalgit | Ritecam | Sotrizol | Suspiria | Tezastin | Virlix | Zirtec</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Allezine | Cerin | Cetolerg | Finallerg | Omcet | Siraz | Zertazine | Zyretic | Zyrtec</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Contac z | Stona rhini z</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acitrin | Actizine | Adco-cetirizine | Alatrol | Alerid | Alfree | Allerta | Altrine | Alzinex | Arcet | Ascet | Atrizex | Atrizin | Cachcet | Ceritec | Cerizine | Ceticad | Cetmax | Cetramac | Cetripinn | Cetriz | Cezine | Citrimin | Contrizet | Copazine | Curtec | Finallerg | Grazine | Histacet | Histarex | Hycet | Osscet | Piricet | Rhizin | Rinacet | Ronex | Satrin | Sitizine | Sulid | Triz | Unicet | Unizine | Zimat | Zycet | Zyncet | Zyrtec</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Albitec | Algyssak ceti | Allercap | Alleren | Allerina | Allershot | Allertec | Alligin | Artec | Arucool | Cenova | Cenova quick | Cerazine | Ceritec | Ceritin | Cetirin | Cetirizine | Cetizine | Cetran | Cirozeno | Conazine a | Florizine | Hulerzine | Jurtec | Kizine | Laricetin | Lergystop | Rizine | Rogitec | Rzn speed | Senoba | Seritex | Serote | Serotec | Srtec | Tallerzi | Tirazen | Ziset | Zyrtec</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Alerid | Cetralon | Glotrizine | Omcet | Rinalgit | Zertazine | Zyrtec</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cetimed | Cetrak | Finallerg | Micet | Rinalgit | Zyrtec</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aceterin | Cetirizine | Zyrtec</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Zyrtec</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cetirizine | Cetrix | Reactin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Airlix | Aler z | Atopix | Cetiral | Cezin | Curtec | Virlix | Zadryl | Zyrtec</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apoliz | Cethexal | Cetirizina | Cetirizina gi serr | Degortzin | Dercetina | Hizidro | Indelin | Kenicet | Miseda | Raamcinet | Retirix | Tradaxin | Virlix | Visertral | Zinobru | Zyrtec | Zyrtex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adezio | Alatrol | Allerzine | Axcel cetirizine | Ceritec | Cetazine | Cetihis | Cetirizine | Cetirizine b | Cetiz | Cetrizet | Cetrizin | Histasin | Intazin | Ricam | Simtec | Stanhist | Sunizine | Triz | Urtirizine | Xetec | Zertin | Zicet | Zirin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Atribex | Atribex pediatric drops | Axcel cetririzine | Cetidyn | Jawazine | Sterizine | Viscetrin | Zyncet</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cetirizine 2 HCl Medcor | Cetirizine 2HCl PCH | Cetirizine dihcl | Cetirizine diHCl A | Cetirizine Dihcl CF | Reactine | Revalintabs | San cetiriz.dihcl | Zyrtec</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Acura | Alzyr | Cetirizin | Cetirizin bmm pharma | Cetirizin sandoz | Reactine | Zyrtec</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aft Cetirizine | Allerid c | Apo cetirizine | Histaclear | Pharmacy health cetirizine hayfever &amp; allergy relief | Razene | Zetop | Zyrtec</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Omcet</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alercet | Alercheck plus | Alerdif | Alerfree c | Alergizina | Alermizol nf | Alerplax | Alertop | Alerxal | Alerzin | Alexmin | Alleghysina | Allercom | Allergizer | Amazina | Antialer | Asint | Cethystan | Cetirizina | Cetirizina diclorhidrato | Cetirizina fmndtria | Cetirizina mf | Cetrikem | Cetrixin | Dulergina | Findaler | Flexmed | Hisaler | Histalen | Hizalab | Lergium | Noalergyn | Pharmaler | Rigotax | Rinacet | Tdn Allergy | Tirizin allergy | Xeniler | Zetaler | Zetix | Zirin | Zyncet | Zyrtec</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aforvir | Alerex | Alergone | Alerid | Aletor | Alfree | Allecur | Allecur P | Allercef | Allerkid | Allermed | Alnix | Antrazine | Askey | Avec | Axella | Boie cetirizine | Cerotec | Ceti med | Cetirizine | Cetizin | Cetrigna | Cetzet | Cetzy | Dialix | Dintec | Ezaller | H One | Histamed | Kalanit | Medan | Medrizine | Prixlae | Qualcet | Reax | Rhinicet | Rhinitrin | Ricam | Ritemed cetirizine | Saphzine | Selergy | Sitizine | Temprazin | Trizin | Unizef | Virlix | Virtec | Welcet | Zericin | Zerlex | Zetir | Zetrix | Zinex | Zyrine | Zyriz | Zyrrigin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Al tak | Alce | Alcit | Alegra | Alergicare | Alergo | Alerid | Alex | Algezen | Allamine | Aller tec | Allergid | Allos | Alzine | Apozine | Arex | Arix | Arozine | Atcet | Avazine | Avec | Azorine | Bytec | Cekim | Cenex | Ceridal | Cerizine | Cetariv | Cetfast | Cetfold | Cetorid | Cetrido | Cetrihit s | Cetrin | Cetrine | Cetrix | Cetroflash | Cezine | Cipzin | Cistazine | Citpharm | Citraclor | Citragic | Citrazit | Citresal | Citrisaf | Ctzine | Czet | Daisy | Davizin | Deebar | Dopnil | Egix | Fastec | Firax | Gixer | Histex | Hozin | Incidal-neo | Instazin | Inzee | Kanzeen | Lgnil | Linazine | Neset | No-all | Nostamin | Rakzine | Rex | Rhizin | Rigix | Rizox | Ronex | Rozen | Sedil | Selzine | Setrizin | Sn zyr | Stamin | Tirix | Trezine | Trine | Xero sed | Z-Tek | Zanlan | Zecit | Zetrine | Zilcit | Zine | Zineva | Zyrtec | Zysic</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Allertec | Amertil | Cetalergin | Cetyryzyna egis | Zyrtec</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">All Day Allergy | Cetirizine | Cetirizine HCL | Children's Cetirizine hydrochloride | Children's Zyrtec | Children's zyrtec allergy | Children's Zyrtec hives relief | Childrens allergy relief | Quzyttir | Zerviate | Zyrtec | Zyrtec allergy | Zyrtec Hives Relief</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cetix | Virlix | Zyrtec</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alergina | Alertop | Antistam | Cerizina | Cetirizina bilac | Cetrizet | Galetrix | Terizin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Allezine | Artiz | Cetralon | Finallerg | Glotrizine | Histazine-1 | Omcet | Zain | Zeran | Zertazine | Ziri-Q | Zyrtec</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cetrine | Reactin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cetirizin | Cetirizin hexal | Cetirizine | Cetrine | Letizen | Parlazin | Solonex | Zetrinal | Zodac | Zyncet | Zyrtec</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cetralon | Citrin | Finallerg | Glotrizine | Nohist | Omcet | Rizino | Zertazine | Zyrtec</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Acura | Cetirizin sandoz | Zyrlex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Adezio | Alzytec | Ceritec | Cetrine | Rhizin | Rizine | Sunizine | Zicet | Zyrtec | Zyrtec r</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cetirizin pharmasan | Letizen | Reactin | Zyrtek</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cetirizin | Parlazin | Zodac | Zyrtec</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aller Go | Celatag | Cetab | Cetihis | Cetrizin | Cettec | Ceza | Cistamine | Cyzine | Histec | Histica | Incidal-od | Mantab | Nytec | One-trex | Ormist | P zine | Pipnaso | Rhitecin | Setin | Tizine | Triz | Utizine | Zaridec | Zensil | Zermed | Zertine | Zetecine | Zetrix | Zittec | Zydon | Zymed | Zyral | Zyrex | Zyrrizin | Zyrrizine | Zyrtec | Zytine | Zytizine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Allergica | Allertec | Arhin | Cetolerge | Zyrtec</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Allerset | Cetiteva | Cetryn | Hitrizin | Lergy | Rynset | Setir | Yenizin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alltec | Cetia | Cetirizine | Minergy | Nonsed | Tirizin | Zocomin | Zyrtec</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Allertec | Cetirizine | Cetrin | Rolinoz | Zyrtec</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Actizine | Alerid | Altrine | Arcet | Ascet | Axcel cetirizine | Cachet | Centrozine | Cetrak | Cetramac | Cetriren | Cezin | Finallerg | Oncet | Stamin | Welbeen | Zyncet</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cetirizina Regueiro</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acitrin | Alatrol | Celay | Cetirina | Cetirivax | Cetirizina | Cetirizina (cetirex) | Cetral | Cetrine | Cetriz | Cliartek | Talerc | Talzic | Virlix | Zyrtec</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bluecezin | Cetirizine stada | Cezil | Cezinefast | Kacerin | Lergitec</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acuzyrt | Allecet | Allesoothe | Aspen cetirizine | Ceticit | Cetirizine hexal | Gulf cetirizine | Kolcrys | Retersic | Sinutab sinus allergy | Texa | Trantrin | Trinicet | Ucb cetirizine | Zelary | Zetop | Zinallerg | Zyrtec</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alatrol | Alerid | Altrine | Cetirizin | Cetirizine | Cetirizine hexal | Cetri | Eze dt | Oncet | Rinacet | Sheltrizine | Texa | Triz | Tryzin | Zimat | Zyncet</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Histacet</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9066452">
<a name="9066452"></a>Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. <i>Arch Intern Med</i>. 1997;157(5):494-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/9066452/pubmed" id="9066452" target="_blank">9066452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19552754">
<a name="19552754"></a>Afonso N, Shetgaonkar P, Dang A, Rataboli PV. Cetirizine-induced anaphylaxis: a rare adverse drug reaction. <i>Br J Clin Pharmacol</i>. 2009;67(5):577-578. doi:10.1111/j.1365-2125.2009.03394.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/19552754/pubmed" id="19552754" target="_blank">19552754</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 169.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Asero.2021">
<a name="Asero.2021"></a>Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1970299">
<a name="1970299"></a>Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR. Effect of haemodialysis on the pharmacokinetics of cetirizine. <i>Eur J Clin Pharmacol</i>. 1990;38(1):67-69. doi:10.1007/BF00314806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/1970299/pubmed" id="1970299" target="_blank">1970299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417. doi: 10.1016/j.jaad.2013.09.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31416456">
<a name="31416456"></a>Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. <i>Ital J Pediatr</i>. 2019;45(1):101. doi: 10.1186/s13052-019-0695-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/31416456/pubmed" id="31416456" target="_blank">31416456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Campbell.1">
<a name="Campbell.1"></a>Campbell RL, Kelso JM. Anaphylaxis: emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Castells.2019">
<a name="Castells.2019"></a>Castells MC, Matulonis UA, Horton TM. Infusion reactions to systemic chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Breckenridge.1">
<a name="Breckenridge.1"></a>Cetirizine hydrochloride oral solution [prescribing information]. Berlin, CT: Breckenridge Pharmaceutical; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Cetirizine tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; February 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211074">
<a name="22211074"></a>Cheng A. Emergency treatment of anaphylaxis in infants and children. <i>Paediatr Child Health</i>. 2011;16(1):35-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/22211074/pubmed" id="22211074" target="_blank">22211074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24673465">
<a name="24673465"></a>Cicardi M, Aberer W, Banerji A et al; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. <i>Allergy</i>. 2014;69(5):602-616. doi: 10.1111/all.12380.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/24673465/pubmed" id="24673465" target="_blank">24673465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31827796">
<a name="31827796"></a>Corsico AG, Leonardi S, Licari A, et al. Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. <i>Multidiscip Respir Med</i>. 2019;14:40. doi:10.1186/s40248-019-0203-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/31827796/pubmed" id="31827796" target="_blank">31827796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33547112">
<a name="33547112"></a>Croitoru D, Brooks SG, Piguet V, MacGillivray L. Cetirizine-induced psychosis in a young adult with erythema multiforme. <i>BMJ Case Rep</i>. 2021;14(2):e241393. doi:10.1136/bcr-2020-241393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/33547112/pubmed" id="33547112" target="_blank">33547112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DelPozzo.1">
<a name="DelPozzo.1"></a>Del Pozzo-Magaña B. Chronic Urticaria in Children: A Review. <i>EMJ Dermatol</i>. 2017;5(1):74-82.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-deShazo.2019">
<a name="deShazo.2019"></a>deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30419768">
<a name="30419768"></a>Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions [published online ahead of print November 12, 2018]. <i>J Oncol Pharm Pract</i>. doi: 10.1177/1078155218811505.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/30419768/pubmed" id="30419768" target="_blank">30419768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10582735">
<a name="10582735"></a>Estelle F, Simons R. H1-receptor antagonists: safety issues. <i>Ann Allergy Asthma Immunol</i>. 1999;83(5):481-488. doi:10.1016/s1081-1206(10)62855-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/10582735/pubmed" id="10582735" target="_blank">10582735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11034010">
<a name="11034010"></a>Fong DG, Angulo P, Burgart LJ, Lindor KD. Cetirizine-induce cholestasis. <i>J Clin Gastroenterol</i>. 2000;31(3):250-253. doi:10.1097/00004836-200010000-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/11034010/pubmed" id="11034010" target="_blank">11034010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23673913">
<a name="23673913"></a>Garden BC, Francois D. Cetirizine-associated delusions and depression in an 18-year-old woman. <i>Clin Neuropharmacol</i>. 2013;36(3):96-97. doi:10.1097/WNF.0b013e318290b9b2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/23673913/pubmed" id="23673913" target="_blank">23673913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10348091">
<a name="10348091"></a>Horak F, Stübner UP. Comparative tolerability of second generation antihistamines. <i>Drug Saf</i>. 1999;20(5):385-401. doi:10.2165/00002018-199920050-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/10348091/pubmed" id="10348091" target="_blank">10348091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081650">
<a name="28081650"></a>James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. <i>Expert Opin Pharmacother</i>. 2017;18(3):253-262. doi: 10.1080/14656566.2017.1282461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/28081650/pubmed" id="28081650" target="_blank">28081650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.2019">
<a name="Khan.2019"></a>Khan DA. Chronic spontaneous urticaria: Standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kirkham.2019">
<a name="Kirkham.2019"></a>Kirkham B. Tumor necrosis factor-alpha inhibitors: An overview of adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10784544">
<a name="10784544"></a>Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. <i>BMJ</i>. 2000;320(7243):1184-1186. doi:10.1136/bmj.320.7243.1184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/10784544/pubmed" id="10784544" target="_blank">10784544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8621847">
<a name="8621847"></a>Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. <i>J Allergy Clin Immunol</i>. 1996;97(2):617-626. doi:10.1016/s0091-6749(96)70307-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/8621847/pubmed" id="8621847" target="_blank">8621847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928731">
<a name="3928731"></a>Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. <i>J Endocrinol Invest</i>. 1985;8(2):143-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/3928731/pubmed" id="3928731" target="_blank">3928731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14754980">
<a name="14754980"></a>Ng KH, Chong D, Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. <i>Pediatrics</i>. 2004;113(2):e116-e121. doi:10.1542/peds.113.2.e116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/14754980/pubmed" id="14754980" target="_blank">14754980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11528239">
<a name="11528239"></a>Noiri E, Ozawa H, Fujita T, Nakao A. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. <i>Nephron</i>. 2001;89(1):101-104. doi:10.1159/000046050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/11528239/pubmed" id="11528239" target="_blank">11528239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15383643">
<a name="15383643"></a>Pompili M, Basso M, Grieco A, Vecchio FM, Gasbarrini G, Rapaccini GL. Recurrent acute hepatitis associated with use of cetirizine. <i>Ann Pharmacother</i>. 2004;38(11):1844-1847. doi:10.1345/aph.1E162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/15383643/pubmed" id="15383643" target="_blank">15383643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25711134">
<a name="25711134"></a>Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy</i>. 2015;45(3):547-565. doi: 10.1111/cea.12494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/25711134/pubmed" id="25711134" target="_blank">25711134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TerSera.1">
<a name="TerSera.1"></a>Quzyttir (cetirizine) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McNeil.1">
<a name="McNeil.1"></a>Reactine (cetirizine) [product monograph]. Markham, Canada: McNeil Consumer Healthcare; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McNeil.2">
<a name="McNeil.2"></a>Reactine 20 mg Tablet (cetirizine) [product monograph]. Markham, Canada: McNeil Consumer Healthcare; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21813500">
<a name="21813500"></a>Romo CA, Joshi KG, Waters BM. Involuntary movements associated with cetirizine use. <i>Am J Psychiatry</i>. 2011;168(8):855. doi:10.1176/appi.ajp.2011.11040534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/21813500/pubmed" id="21813500" target="_blank">21813500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856-889.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17620060">
<a name="17620060"></a>Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. <i>Allergy</i>. 2007;62(8):830-837. doi: 10.1111/j.1398-9995.2007.01435.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/17620060/pubmed" id="17620060" target="_blank">17620060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21377030">
<a name="21377030"></a>Simons FE, Ardusso LR, Bilò MB, et al; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. <i>J </i>
<i>Allergy Clin Immunol</i>. 2011;127(3):587-593.e1-22. doi: 10.1016/j.jaci.2011.01.038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/21377030/pubmed" id="21377030" target="_blank">21377030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525001">
<a name="26525001"></a>Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. <i>World Allergy Organ J</i>. 2015;8(1):32. doi: 10.1186/s40413-015-0080-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/26525001/pubmed" id="26525001" target="_blank">26525001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10384858">
<a name="10384858"></a>Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. <i>Clin Pharmacokinet</i>. 1999;36(5):329-352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/10384858/pubmed" id="10384858" target="_blank">10384858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336054">
<a name="29336054"></a>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i>. 2018;73(7):1393-1414. doi: 10.1111/all.13397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cetirizine-systemic-drug-information/abstract-text/29336054/pubmed" id="29336054" target="_blank">29336054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.2019">
<a name="Zuraw.2019"></a>Zuraw B. An overview of angioedema: Clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McNeil.3">
<a name="McNeil.3"></a>Zyrtec Allergy (cetirizine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; received May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Zyrtec (cetirizine hydrochloride) [prescribing information]. New York City, NY: Pfizer Labs; May 2006.</div>
</li></ol></div><div id="topicVersionRevision">Topic 113446 Version 580.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
